Asia Pacific Filgrastim Market Size & Share Forecast to 2027

Asia Pacific Filgrastim Market By Drug Type (Biosimilar and Biologic), By Indication (Chemotherapy induced Neutropenia, Chronic Neutropenia and Other Indications), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies), By Country, Opportunity Analysis and Industry Forecast, 2021 - 2027

Published Date: December-2021 | Number of Pages: 82 | Format: PDF | Report ID: KBV-16051

Special Offering: Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support


Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Asia Pacific Filgrastim Market, by Drug Type
1.4.2 Asia Pacific Filgrastim Market, by Indication
1.4.3 Asia Pacific Filgrastim Market, by Distribution Channel
1.4.4 Asia Pacific Filgrastim Market, by Country
1.5 Methodology for the research

Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints

Chapter 3. Asia Pacific Filgrastim Market by Drug Type
3.1 Asia Pacific Biosimilar Market by Country
3.2 Asia Pacific Biologic Market by Country

Chapter 4. Asia Pacific Filgrastim Market by Indication
4.1 Asia Pacific Chemotherapy induced Neutropenia Market by Country
4.2 Asia Pacific Chronic Neutropenia Market by Country
4.3 Asia Pacific Other Indications Market by Country

Chapter 5. Asia Pacific Filgrastim Market by Distribution Channel
5.1 Asia Pacific Hospital Pharmacies Market by Country
5.2 Asia Pacific Retail Pharmacies Market by Country
5.3 Asia Pacific Online Pharmacies Market by Country

Chapter 6. Asia Pacific Filgrastim Market by Country
6.1 China Filgrastim Market
6.1.1 China Filgrastim Market by Drug Type
6.1.2 China Filgrastim Market by Indication
6.1.3 China Filgrastim Market by Distribution Channel
6.2 Japan Filgrastim Market
6.2.1 Japan Filgrastim Market by Drug Type
6.2.2 Japan Filgrastim Market by Indication
6.2.3 Japan Filgrastim Market by Distribution Channel
6.3 India Filgrastim Market
6.3.1 India Filgrastim Market by Drug Type
6.3.2 India Filgrastim Market by Indication
6.3.3 India Filgrastim Market by Distribution Channel
6.4 South Korea Filgrastim Market
6.4.1 South Korea Filgrastim Market by Drug Type
6.4.2 South Korea Filgrastim Market by Indication
6.4.3 South Korea Filgrastim Market by Distribution Channel
6.5 Singapore Filgrastim Market
6.5.1 Singapore Filgrastim Market by Drug Type
6.5.2 Singapore Filgrastim Market by Indication
6.5.3 Singapore Filgrastim Market by Distribution Channel
6.6 Malaysia Filgrastim Market
6.6.1 Malaysia Filgrastim Market by Drug Type
6.6.2 Malaysia Filgrastim Market by Indication
6.6.3 Malaysia Filgrastim Market by Distribution Channel
6.7 Rest of Asia Pacific Filgrastim Market
6.7.1 Rest of Asia Pacific Filgrastim Market by Drug Type
6.7.2 Rest of Asia Pacific Filgrastim Market by Indication
6.7.3 Rest of Asia Pacific Filgrastim Market by Distribution Channel

Chapter 7. Company Profiles
7.1 Abbott Laboratories
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental and Regional Analysis
7.1.4 Research & Development Expense
7.2 Amgen, Inc.
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Regional Analysis
7.2.4 Research & Development Expenses
7.3 Pfizer, Inc.
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Regional Analysis
7.3.4 Research & Development Expense
7.3.5 Recent strategies and developments:
7.3.5.1 Approvals and Trials:
7.4 Novartis AG
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Segmental and Regional Analysis
7.4.4 Research & Development Expense
7.4.5 Recent strategies and developments:
7.4.5.1 Product Launches and Product Expansions:
7.5 Dr. Reddy’s Laboratories Ltd.
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Segmental and Regional Analysis
7.5.4 Research & Development Expense
7.5.5 Recent strategies and developments:
7.5.5.1 Partnerships, Collaborations, and Agreements:
7.5.5.2 Product Launches and Product Expansions:
7.6 Teva Pharmaceutical Industries Ltd.
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Regional Analysis
7.6.4 Research & Development Expenses
7.6.5 Recent strategies and developments:
7.6.5.1 Approvals and Trials:
7.7 Kyowa Kirin Co., Ltd. (Kirin Company)
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Regional Analysis
7.7.4 Research & Development Expense
7.7.5 Recent strategies and developments:
7.7.5.1 Partnerships, Collaborations, and Agreements:
7.8 Cadila Healthcare Ltd. (Zydus Cadila)
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Segmental and Regional Analysis
7.8.4 Research & Development Expense
7.9 Apotex, Inc.
7.9.1 Company Overview
7.9.2 Recent strategies and developments:
7.9.2.1 Product Launches and Product Expansions:
7.10 Toksöz Group
7.10.1 Company Overview

Purchase Report

 1500
 1800
 2520

Special Pricing & Discounts

  • Buy Sections of This Report
  • Buy Country Level Reports
  • Request for Historical Data
  • Discounts Available for Start-Ups & Universities